CuraSen Therapeutics, a San Carlos, CA-based clinical-stage company developing small molecule therapies to treat neurodegenerative disease, received up to $5.8M in investment from Alzheimer’s Drug Discovery Foundation (ADDF).
The company intends to use the funds to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease.
Led by CEO Anthony Ford, CuraSen is focused on the development of new treatments for neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and other related orphan conditions. Its drugs are designed to activate certain receptor populations in the brain to compensate for critical neuronal and glial functions that have otherwise been lost due to degeneration and represent a unique approach in the field. The company is evaluating CST-103 and CST-2032, both selective β2-ARs agonists, in combination with CST-107, a β-AR blocker, in multiple Phase 2 clinical studies. CST-3056, an α1A-AR agonist, is in preclinical development for the treatment of Alzheimer’s disease.
CuraSen will commence non-clinical studies early in 2024 and expects to initiate Phase 1 clinical testing later that year.
FinSMEs
16/10/2023